News

News 22.02.2024 SCHLIEREN, Switzerland--(BUSINESS WIRE)--LimmaTech Biologics AG announced positive interim data from its Phase I/II clinical trial evaluating Shigella4V (S4V), a tetravalent bioconjugate vaccine candidate against shigellosis, an infectious disease caused by Shigella bacteria. Shigellosis is a serious infection and remains the second leading cause of fatal diarrheal disease, particularly in infants...

News 14.02.2024 Switzerland, 14 February 2024 – CUTISS AG, a Swiss clinical-stage life science company focused on skin regenerative medicine and tissue engineering, has announced positive one-year follow-up data from its Phase 2 clinical trial of the lead product denovoSkin™, in adult and adolescent severe burn patients. Following the announced positive primary endpoint in Q1...

News 06.02.2024 Schlieren / Zurich, Switzerland, February 5, 2024 – Memo Therapeutics AG (or “MTx”), a late-stage biotech company developing best-in-class therapeutic antibodies for viral infections and oncology, announced today that it has strengthened its senior team with the appointments of Kristie B. Clemmer and Dr. Maartje Verschuur as VP Clinical Operations and...

News 04.02.2024 Schlieren (Zurich), February 01, 2024 – LimmaTech Biologics today announced a second closing of its Series A financing, raising an additional USD 3 million from new investor Tenmile, bringing the total raised to USD 40 million (CHF 34,7 million). The funding will be utilized to further advance the company’s proprietary...

News 01.02.2024 Zurich, Switzerland - 31.01.2024 Neurimmune aims to develop aducanumab-based therapeutics that can be subcutaneously administered Neurimmune announced today that it regained global rights to aducanumab, a recombinant human antibody developed to deplete brain amyloid. Aducanumab was granted FDA accelerated approval for the treatment of Alzheimer’s disease. Neurimmune licensed its antibody aducanumab for...